Background-Several studies have compared short-term and medium-term mortality rates for patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR), but no studies have compared short-term readmission rates for the 2 procedures. Methods and Results-New York's Cardiac Surgery Reporting System was used to propensity match 617 TAVI and 1981 SAVR patients using numerous patient risk factors contained in the registry. The 389 propensity-matched pairs were then used to analyze differences in readmission rates between the 2 groups. TAVI and SAVR readmission rates were also compared for patients with a history of congestive heart failure and for patients aged ≥80. Also, reasons for readmission for TAVI and SAVR patients were examined and compared. Readmission rates were not statistically different for all propensitymatched TAVI and SAVR patients (respective rates, 18.8% and 19.3%; P=0.86). After further adjustment using a logistic regression model, there was still no significant difference (adjusted odds ratio, 0.97; 95% confidence interval [0.68-1.39]). For patients aged ≥80, the 30-day readmission rates were 19.9% and 22.0% (P=0.59), and when further adjusted using the logistic regression model, adjusted odds ratio=0.89 (0.55-1.45). For patients with a history of congestive heart failure, the respective rates were 22.8% and 20.4% (P=0.56), and with further adjustment, adjusted odds ratio became 1.15 (0.72-1.82). Conclusions-There are no statistically significant differences between TAVI and SAVR patients in short-term readmission rates. (Circ Cardiovasc Interv. 2015;8:e002744.
P atients with symptomatic severe aortic stenosis with symptomatic presentation or compromised (<50%) ejection fractions have poor prognoses and high mortality rates with medical treatment alone. These patients are typically treated with surgical aortic valve replacement (SAVR), but many of them have been of too high risk for SAVR and have traditionally been treated medically. However, with the introduction of transcatheter aortic valve implantation (TAVI), many of these high-risk patients have received nonsurgical valve implantations. There have been numerous randomized controlled trials and observational studies that have compared SAVR and TAVI, with encouraging results for TAVI patients. As a consequence, TAVI has recently been used for moderate-risk and high-risk patients. Nevertheless, information about the use of TAVI in standard practice is limited, based on small samples, and restricted to mortality and complications.
Given that TAVI is less invasive than SAVR, one might hypothesize that readmission rates will be less with TAVI. This has not been tested in a rigorous manner. Therefore, the purpose of this study is to compare 30-day readmission rates for TAVI and SAVR while controlling for differences in preprocedural severity of illness using a large observational database.
Methods Databases
The primary database used for the analyses is New York's Cardiac Surgery Reporting System (CSRS) which is a clinical registry developed in New York in 1989 that, since its inception, has been used by the New York State Department of Health to publicly release riskadjusted mortality rates for coronary artery bypass graft surgery and cardiac valve surgery. These reports contain risk-adjusted mortality rates for hospitals and surgeons and are released on an annual basis. Data in the system include patient demographics (age, sex, race, etc), numerous patient risk factors and comorbidities, patient disposition, complications of care, and hospital and surgeon identifiers. Data from the CSRS are checked annually for completeness and for accuracy of the in-hospital mortality measure by matching the records to the Statewide Planning and Research Cooperative System, New York's administrative acute care database. The accuracy of risk factors in the system is checked by using New York's utilization review agent to audit samples of cases from selected hospitals each year. The CSRS contains data for most open heart procedures, including coronary artery bypass graft surgery and valve surgery.
Data from New York's administrative acute care database, the Statewide Planning and Research Cooperative System, which contains all acute care discharges from nonfederal hospitals in the state, were matched to CSRS using unique patient identifiers to obtain 30-day readmission rates for TAVI and SAVR. Statewide Planning and Research Cooperative System data were also used to examine reasons for readmission for both TAVI and SAVR patients using the principal diagnosis reported for each readmission. The principal diagnosis represents the diagnosis that was chiefly responsible for occasioning the hospital admission.
Patients and Hospitals
Candidate patients in the study include all 5051 New York State residents undergoing aortic valve replacement or implantation in New York hospitals using either SAVR or TAVI between January 1, 2011 and November 30, 2012. The study was limited to New York State residents to minimize any bias introduced by patients being readmitted to out-of-state hospitals. Cases were then excluded if the patient died during the index hospitalization (n=113). The observed in-hospital/30-day mortality rates for TAVI and SAVR patients before propensity matching were 5.4% and 2.4% (4.5% and 1.9% for in-hospital rates), respectively. Another 1498 patients were excluded because they underwent SAVR in a hospital in which TAVI was not performed during the study period. Further exclusions were for patients with characteristics primarily associated with one of the 2 procedures: 516 patients without severe aortic stenosis (506 SAVR; 10 TAVI), 495 aged <60, 495 (491 SAVR; 4 TAVI), 26 aged at least 95 (2 SAVR; 24 TAVI), 85 with endocarditis (85 SAVR; 0 TAVI), 5 with unstable hemodynamics (5 SAVR; 0 TAVI), 2 with an acute myocardial infarction in the previous 24 hours (2 SAVR; 0 TAVI), and 5 with hepatic failure (4 SAVR; 1 TAVI). Before propensity matching of the 2 procedures to adjust for relative risk, there were a total of 1981 SAVR patients and 617 TAVI patients. Because the analysis was based on intention to treat, the 3 patients who converted from TAVI to SAVR were treated as part of the TAVI group. Hospitals in the study include all 16 hospitals in which TAVI procedures were performed during the time period of the study. Hospital volumes for all aortic valve replacements/implantations ranged from 69 to 1021 for the study period, with an interquartile range from 129 to 357.
Outcome
The outcome of interest was 30-day all-cause readmission rate.
Data Analysis
The prevalences of all available patient risk factors were compared for SAVR and TAVI patients, and standardized differences of observed prevalences were calculated for all of the variables. Because patients were not randomized to TAVI and SAVR and because many patient risk factors had large differences in prevalence between TAVI and SAVR patients, propensity-score matching was used to identify a set of TAVI/SAVR pairs matched on those characteristics so that the selection bias associated with our observational study could be minimized. The propensity score was derived by developing a logistic regression model that predicted the probability that a given patient would receive TAVI on the basis of all of the risk factors available in the registry. Before propensity matching, all patients were grouped by hospital to ensure that matched pairs would always be from the same hospital. This was done to minimize bias because of practice pattern differences among hospitals.
Then, the propensity score was used to match patients on a 1-to-1 basis without replacement so as to minimize the overall distance in propensity scores between the groups. [23] [24] [25] [26] Patients from the TAVI and SAVR groups were matched using a caliper of width 0.2× the SD of the logit of the propensity score. Standardized differences in the prevalence of propensity model variables were then recalculated. 27 The propensity-matched pairs were then used to analyze differences in readmission rates between the 2 groups using McNemar test for paired observations. Remaining differences in the 22 groups were adjusted for using a pair-matched logistic regression model, and adjusted odds ratio (AOR) was calculated. In addition to comparing overall outcomes for TAVI and SAVR patients, TAVI and SAVR readmission rates were also compared for patients with congestive heart failure and for patients aged ≥80. Furthermore, reasons for readmission (principal diagnoses from Statewide Planning and Research Cooperative System) for TAVI and SAVR patients were examined and contrasted. All tests were 2-sided and conducted at the 0.05 level, and all analyses were conducted in SAS 9.2 (SAS Institute, Cary, NC).
Results
After exclusions, 617 (23.7%) TAVI patients and 1981 (76.3%) SAVR patients were candidates for propensity matching. The standardized differences in prevalences for most risk factors exceeded the recommended maximum value of 10%, with TAVI patients generally having higher prevalences (Data Supplement). A total of 389 pairs resulted from the propensity match. The propensity model has a good discrimination with C-statistic of 0.89 and good calibration (P=0.13). Also, standardized differences for all variables were lower than the typical cutoff of 10% for this measure, which indicates a well-balanced case mix between the SAVR and TAVI matched cohorts (Table 1) . Table 2 presents the 30-day readmission rates for all propensity-matched patients, for the subgroup of patients aged ≥80, for the subgroup with congestive heart failure, and for the subgroup based on the TAVI transfemoral approach. As noted in Table 2 , the readmission rates were similar and not statistically different for all propensity-matched TAVI and SAVR patients (respective
WHAT IS KNOWN
• Relative short-term and medium-term mortality rates for patients undergoing transcatheter aortic valve implantation and surgical aortic valve replacement are favorable, but short-term readmission rates are not known.
WHAT THE STUDY ADDS
• This registry study demonstrated that short-term 30-day readmission rates for transcatheter aortic valve implantation and surgical aortic valve replacement were high (≈20%) but were not significantly different between the 2 procedures. rates, 18.8% and 19.3%; P=0.86). After further adjustment using a logistic regression model, there was still no significant difference (AOR, 0.97; 95% confidence interval [0.68-1.39]). For patients who were at least 80 years old, the 30-day readmission rates were 19.9% and 22.0 for TAVI and SAVR patients, respectively (P=0.59), and when further adjusted using the logistic regression model, AOR=0.89 (0.55-1.45). For patients with congestive heart failure, the respective rates were 22.8% and 20.4% (P=0.56), and with further adjustment, AOR=1.15 (0.72-1.82).
The respective median length of stay for TAVI and SAVR patients in their index admissions was 8 days (interquartile range and 11 days (15-7). The median lengths of stay for readmitted patients were 5 days (8-2) and 6 days (9-3). The median total lengths of stay for index admissions plus readmissions (where readmission is counted as 0 days when there is none) were 9 days (14-6) and 11 days .
The 30-day readmissions within 0 to 3 days were almost identical (15 for SAVR; 14 for TAVI), and the readmissions between 21 and 30 days were identical . There were more SAVR readmissions between 4 and 10 days (28 versus 19), but more TAVI readmissions between 11 and 20 days (18 versus 24). Table 3 presents the most frequent principal diagnoses for readmitted patients in the propensity-matched cohort for SAVR and TAVI patients, respectively. The most frequent reasons for readmission of SAVR patients within 30 days were heart failure (19.2%), cardiac rhythm disorders (9.6%), stroke or transient ischemic attack (5.5%), pneumonia (5.5%), pneumothorax/pleural effusion (5.5%), and gastrointestinal bleeding (5.5%). For TAVI patients, the most frequent reasons for readmission within 30 days were heart failure (21.9%), postoperative infection (11.0%), hemorrhage or hematoma (5.5%), stroke or transient ischemic attack (4.1%), and respiratory failure (4.1%). The numbers of TAVI and SAVR patients with the combined major adverse cardiac event of myocardial infarction/stroke/reoperation were 1 patient (0.26%) for TAVI and 4 patients (1.03%) for SAVR. Using a primary end point of 30-day all-cause mortality, major stroke, or renal failure requiring dialysis, the trial was ended prematurely by the data safety monitoring board because of an excess of end-point events in the TAVI group (14.7% versus 2.8%; P=0.07).
In the US CoreValve High Risk Study in 2014, Adams et al 4 randomized high-risk surgical patients to undergo TAVI or SAVR in 45 centers in the United States. With a primary end point of all-cause mortality at 1 year, the authors found a significantly lower rate for TAVI (14.2% versus 19.1%; P=0.04).
In a meta-analysis of 11 nonrandomized trials, Cao et al 5 found that there was no significant difference between TAVI and SAVR in periprocedural all-cause in-hospital/30-day mortality (8.4% versus 7.2%; relative risk, 1.24; 95% confidence interval [0.92-1.62]). Despite the randomized and nonrandomized trials just mentioned, we are not aware of any studies that have compared short-term or longer-term readmissions for TAVI and SAVR. The purpose of this study was to examine differences in shortterm (30-day) readmissions for the 2 procedures using New York's observational registry, the CSRS. Because this was an observational study, patients were propensity matched before comparing readmission rates to minimize the selection bias.
Not surprisingly, we found that TAVI patients were older and sicker than SAVR patients before propensity matching. However, after propensity matching, the 2 groups of patients were similar, with no patient characteristics having a standardized difference of >10%. Nevertheless, we further adjusted for remaining differences using a logistic regression model for paired groups. After propensity matching, we found that the TAVI and SAVR readmission rates were close (respective rates, 18.8% and 19.3%; P=0.86). After further adjustment using a logistic regression model, there was still no significant difference (AOR, 0.97; 95% confidence interval [0.68-1.39]). There were also no significant differences among patients aged ≥80 or patients with heart failure. At close to 20%, the readmission rates for both TAVI and SAVR were somewhat higher than 16.5% that was reported in a recent study on coronary artery bypass graft surgery readmissions in New York. 28 Reasons for readmission of TAVI and SAVR patients were similar, but there were differences. Patients undergoing both procedures were most likely to be readmitted because of heart failure (22% and 19%, respectively). However, the next most likely reason for TAVI patients was postoperative infection (11%), which was not among the leading reasons for SAVR readmissions. The second most common reason for SAVR readmissions was cardiac rhythm disorders (10%), which was not among the most frequent reasons for TAVI readmissions. Stroke/transient ischemic attack, although not the major reason for readmission for either procedure, was among the leading reasons for readmission for both procedures.
There are a few caveats associated with the study. First, as with other observational studies, these results are subject to potential selection biases in comparison with the results from randomized controlled trials. We attempted to minimize bias by using the best available methods to propensity-matched patients based on numerous patient characteristics. Propensity matching has been used in numerous other observational studies comparing competing procedures and is regarded as one of the best methods for minimizing selection bias. Also, to remove the possibility that hospitals with lower readmission rates had higher percentages of either TAVI or SAVR, we ensured that all matched pairs came from the same hospital.
The typical statistic for measuring the quality of the match (percent standardized difference in prevalence) indicates that none of the numerous matching characteristics exceeded the recommended limit of 10%. Also, the propensity analyses were further adjusted by using logistic regression models to adjust for differences that remained after propensity matching. Thus, we did everything possible to minimize selection bias with the database we had. However, it should be noted that it would be ideal to have had access to variables, such as frailty, severe hepatic disease without failure, severe pulmonary hypertension, and cognitive impairment when developing the risk index. Also, we did not have access to socioeconomic status, which may have been related to selection bias. It is also important to note that the process of propensity matching eliminated many highrisk TAVI patients and low-risk SAVR patients because they could not be matched with similar patients undergoing the other procedure.
We were also unable to separately compare transfemoral and transapical TAVIs with SAVR because the vast majority of TAVI patients underwent transfemoral TAVIs (only 41 underwent transapical TAVIs). Thus, we were only able to assess the relative readmission rate for the TAVI transfemoral approach compared with the SAVR rate.
